Can therapy of hepatitis C affect the development of hepatocellular carcinoma?

Laura M. Kulik*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Chronic inflammation induced by viral infections and their role in carcinogenesis is well recognized. Two hepatotropic viruses, hepatitis B and hepatitis C (HCV), have been linked worldwide to the development of hepatocellular carcinoma (HCC). Although orthotopic liver transplant offers the best chance for cure and long-term survival, the demand for organs far outweighs the supply. The incidence of HCC in the United States has increased over the past 3 decades. HCV-induced cirrhosis is believed to play a significant role in the rising rate of HCC. Therefore, primary measures to prevent HCC in HCV-infected patients are urgently needed. Numerous studies of the HCV HCC patient have considered primary treatment with interferon-based therapy. However, secondary prevention currently seems to carry more promise. This article evaluates and assesses various treatments for primary and secondary chemoprevention in the setting of HCV.

Original languageEnglish (US)
Pages (from-to)751-757
Number of pages7
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number8
StatePublished - Sep 2006


  • Chemoprevention
  • Cirrhosis
  • HCV
  • Hepatitis
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Can therapy of hepatitis C affect the development of hepatocellular carcinoma?'. Together they form a unique fingerprint.

Cite this